Aug 01, 2022 7:00am EDT Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
Jul 14, 2022 7:00am EDT Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
May 12, 2022 7:00am EDT Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month
May 05, 2022 7:00am EDT Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
May 03, 2022 4:01pm EDT Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights
Apr 26, 2022 7:15am EDT Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors
Apr 22, 2022 7:00am EDT Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET
Mar 14, 2022 7:00am EDT Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting
Mar 10, 2022 4:05pm EST Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights
